Fujifilm Biotechnologies Will Seek Three CPHI Pharma Awards
The firm aims for industry recognition in Milan this October, highlighting its current biomanufacturing platform and enzyme technology.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Will industry-awarded innovations lead to measurable improvements in future biomanufacturing efficiency?
Fujifilm Biotechnologies is set to receive evaluation for three CPHI Pharma Awards during the upcoming conference in Milan. The nominations recognize the firm's leadership, its MaruX biomanufacturing platform, and its ShunzymeX technology.
Why it matters
These nominations spotlight the current trajectory of integrated biomanufacturing platforms, which are increasingly evaluated on their ability to catalyze innovation and streamline API development. Fujifilm's participation centers on industry-wide strategies for scaling these technologies.
Fujifilm Biotechnologies secured three award nominations, including recognition for the MaruX manufacturing platform and the ShunzymeX API (active pharmaceutical ingredient) development technology. The firm will further detail its operational capabilities at booth 8A2.
The players
Fujifilm Biotechnologies
A developer of biomanufacturing platforms and contract development services for the pharmaceutical industry.
Maja Pedersen
The Chief Operating Officer at Fujifilm Biotechnologies, nominated for Woman of the Year.
The details
The firm plans to use the conference to host speaking sessions on global biomanufacturing strategy and conduct partnering meetings. The MaruX platform represents an integrated approach to process development, while ShunzymeX focuses on enzyme-based methods for API synthesis, a process that converts chemical precursors into active drug components. These initiatives aim to address current complexities in scaling pharmaceutical production for global markets.
Timeline
October 6, 2026: Christiane Bardroff will lead a speaking session.
October 7, 2026: Christian Houborg and Jonathan Haigh will deliver speaking sessions.
The Tech Race
The CPHI Pharma Awards function as a primary industry benchmark for the viability of new manufacturing architectures. Fujifilm's multi-category entry reflects the competitive race to demonstrate the maturity of proprietary platforms like MaruX against legacy batch processing standards.
Industry participants and partners can engage with the firm at booth 8A2 during the conference to review the performance data of the MaruX and ShunzymeX systems. These platforms directly influence the speed and cost-efficiency of global pharmaceutical manufacturing pipelines.
The takeaway
The nominations highlight the growing focus on integrated platform efficiency within the biomanufacturing sector. Watch for the official announcement of the CPHI award winners on October 7 to confirm if these technologies successfully outperformed established industry peers.
What happens next
The CPHI conference will take place in Milan starting October 6, 2026, where the final winners for the three award categories are expected to be announced.
Further reading
For broader trends in industry-leading manufacturing platforms, see Biotech.
Source note: This article includes information reported by Manufacturingchemist.
Live Poll
Will industry-awarded innovations lead to measurable improvements in future biomanufacturing efficiency?
